Doctors Note Logo

Published on: 10/1/2026

Is the shingles vaccine a live virus, and what changed with Shingrix

Shingrix, the only shingles vaccine available in the United States, is not a live virus vaccine; it is a recombinant, adjuvanted vaccine that uses a single viral protein plus an immune booster, given as two doses. The older option, Zostavax, was a live attenuated vaccine that was discontinued in the U.S. in November 2020, which is why people who are immunocompromised can now be vaccinated when they previously could not. Eligibility, timing between doses, and what to expect for side effects differ by age and immune status, and there are several important details to consider. See below for the complete answer, including who should get vaccinated and what to do if you already received Zostavax.

If you are weighing vaccination because of a painful rash, tingling, or burning skin that is already developing, timing matters, since antiviral treatment for shingles works best within the first 72 hours of symptoms. A free, instant, online symptom check can help you sort out whether what you are feeling looks like shingles, a different rash, or nerve pain, and point you toward the right next step and level of care.

Last reviewed for medical accuracy: 10/01/2026

answer background

Explanation

Is the shingles vaccine a live virus? What changed with Shingrix?

Shingles (herpes zoster) is a painful rash caused by reactivation of the chickenpox virus (varicella-zoster virus) in people who’ve had chickenpox before. Vaccination is the best way to prevent shingles and its complications. You may wonder, “Is the shingles vaccine a live virus?” The answer depends on which vaccine you’re looking at. Below, you’ll find clear, concise information—backed by the Centers for Disease Control and Prevention (CDC) and other credible sources—about the two main shingles vaccines, how they work, and why Shingrix represents a major advance.

Live-Attenuated vs. Recombinant: Vaccine Types

  1. Zostavax® (Live-Attenuated Vaccine)

    • Contains a weakened (attenuated) form of the varicella-zoster virus.
    • Works by stimulating your immune system to recognize and fight the virus if it reactivates.
    • Typically given as a single injection.
    • Approved by the FDA in 2006.
  2. Shingrix® (Recombinant Subunit Vaccine)

    • Does not contain live virus.
    • Made from a specific protein (glycoprotein E) of the varicella-zoster virus, combined with an adjuvant (AS01B) that boosts your immune response.
    • Administered in two doses, 2 to 6 months apart.
    • Approved by the FDA in 2017.

Key takeaway: If you’re asking “is the shingles vaccine a live virus,” the answer is “it depends.” Zostavax is live-attenuated; Shingrix is non-live (recombinant).

Why Shingrix Changed the Game

When Shingrix was introduced, it quickly became the preferred shingles vaccine for these reasons:

  • Higher Efficacy

    • Shingrix prevents over 90 percent of shingles cases in adults aged 50–69, and about 85 percent in those 70 and older.
    • By comparison, Zostavax’s effectiveness is around 50 percent and declines significantly over time.
  • Longer-Lasting Protection

    • Studies show Shingrix maintains strong protection for at least four years after vaccination, with ongoing studies to define longer-term durability.
    • Zostavax’s protection drops by roughly half within 5 years.
  • Safety Profile

    • Common side effects with Shingrix are injection-site pain, redness, swelling, fatigue, muscle pain, and headache.
    • Most reactions are mild to moderate and resolve within 2–3 days.
    • Because it’s non-live, Shingrix can be used in some people with weakened immune systems (though you should always check with your doctor).
  • Broader Eligibility

    • Shingrix is recommended for adults aged 50 and older, including those who previously received Zostavax.
    • It can also be given to people who have had shingles before to boost their immunity against recurrence.

Who Should Get the Shingles Vaccine?

  • Age 50 and older: The CDC recommends Shingrix for all healthy adults in this age group, even if they had shingles or Zostavax before.
  • Immunocompromised individuals: Because Shingrix is non-live, many people with weakened immune systems can safely receive it—pending a doctor’s assessment.
  • People with a history of chickenpox: Since nearly all adults have been exposed to varicella-zoster, vaccination helps prevent the reactivation that leads to shingles.

Common Questions

Q: Can I get Shingrix if I already had Zostavax?
A: Yes. The CDC advises that people previously vaccinated with Zostavax still get Shingrix for stronger, longer-lasting protection. Wait at least 8 weeks after Zostavax before starting Shingrix.

Q: Do I need a live-virus vaccine if I’m immune-compromised?
A: No. In many cases, Shingrix (non-live) is a safer choice for people with certain immune conditions. Always discuss your specific health situation with your doctor.

Q: What if I’ve had shingles before?
A: Even if you’ve had shingles, Shingrix can help prevent future episodes. Talk to your doctor about timing—typically you wait until the rash has cleared.

Side Effects and What to Expect

Most people tolerate Shingrix well. Common reactions include:

  • Injection-site pain, redness or swelling
  • Fatigue
  • Muscle pain
  • Headache
  • Shivering
  • Fever
  • Stomach pain (less common)

These effects usually peak within 1–2 days and resolve quickly. If you experience severe or persistent symptoms, contact your healthcare provider.

Staying Informed and Taking Action

Vaccination decisions are personal and should be made in consultation with your healthcare professional. If you’re unsure about your symptoms or need personalized guidance, consider doing a
free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to help you decide whether to seek medical care.

When to Speak to a Doctor

  • If you have a weakened immune system (e.g., cancer treatment, HIV, organ transplant), vaccination plans may differ.
  • If you develop a severe reaction after vaccination (high fever, difficulty breathing, hives), seek immediate medical attention.
  • Always consult your doctor before starting any vaccine, especially if you have ongoing health conditions or allergies.

This information is intended to help you make informed decisions. Nothing here replaces personalized medical advice. If you have any concerns—particularly anything that could be serious or life threatening—please speak to a doctor right away.

(References)

  • * Gelb LD. Reducing the incidence and severity of herpes zoster and PHN with zoster vaccination. J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S18-21. PMID: 19553631.

  • * Cogman AR, Chakravarty EF. The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine. 2013 Aug 12;31(36):3640-3. doi: 10.1016/j.vaccine.2013.05.085. Epub 2013 Jun 3. PMID: 23742992; PMCID: PMC3952213.

  • * Oxman MN, Schmader KE. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014 Oct;59(7):920-2. doi: 10.1093/cid/ciu501. Epub 2014 Aug 4. PMID: 25097080.

  • * Whitley RJ. Editorial commentary: Waning efficacy of the herpes zoster vaccine. Clin Infect Dis. 2015 Mar 15;60(6):910-1. doi: 10.1093/cid/ciu922. Epub 2014 Nov 20. PMID: 25416752.

  • * Oxman MN, Harbecke R, Koelle DM. Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine. J Infect Dis. 2017 Dec 12;216(11):1329-1333. doi: 10.1093/infdis/jix484. PMID: 29029303; PMCID: PMC5853975.

  • * Morgado-Carrasco D, Fustà-Novell X, Giavedoni P. RF-New Recombinant Vaccine for the Prevention of Herpes Zoster. Actas Dermosifiliogr (Engl Ed). 2020 Jan 2;111(1):67-68. doi: 10.1016/j.ad.2018.06.020. Epub 2019 Aug 3. PMID: 31387689.

  • * Lu PJ, Hung MC, Srivastav A, Williams WW, Dooling KL. Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine. Am J Prev Med. 2020 Jul;59(1):21-31. doi: 10.1016/j.amepre.2020.01.017. Epub 2020 May 7. PMID: 32389533; PMCID: PMC9196997.

  • * Callegaro A, Burny W, Hervé C, Hyung Kim J, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. J Infect Dis. 2022 Nov 28;226(11):1943-1948. doi: 10.1093/infdis/jiab536. PMID: 34662415; PMCID: PMC9704432.

  • * Kupa LVK, Medeiros-Ribeiro AC, Aikawa NE, Pasoto SG, Borba EF, Assad APL, Saad CGS, Yuki EFN, Seguro LPC, Andrade D, Shinjo SK, Sampaio-Barros PD, Shimabuco AY, Moraes JCB, Sampaio VS, Giardini HAM, Silva CAA, Bonfá E. Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 Study. J Clin Rheumatol. 2025 Sep 1;31(6):e104-e111. doi: 10.1097/RHU.0000000000002216. Epub 2025 Mar 4. PMID: 40036115.

  • * Ark R, Allen V, Bechman K, Yang Z, Nagra D, Russell MD, Galloway J. Shingles vaccination in immune-mediated inflammatory diseases: a narrative review. Rheumatology (Oxford). 2026 Feb 4;65(2). doi: 10.1093/rheumatology/keag043. PMID: 41578947.

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.